


PARG-IN-4

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 2988890-20-4 |
| Formula: | C ₂₀ H ₂₅ F ₂ N ₇ O ₂ S ₂ |
| Molecular Weight: | 497.59 |
| Storage: | Keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i> |



Biological Description

| | |
|----------------------------|--|
| Description | PARG-IN-4 (compound A) is an orally active and cell-membrane permeable PARG inhibitor (EC ₅₀ =1.9 nM) that inhibits tumour growth in mice with antitumour activity. |
| Targets(IC ₅₀) | Apoptosis, Poly(ADP-ribose) Glycohydrolase (PARG) |
| In vitro | PARG-IN-4 shows strong anti-proliferative effects against ovarian and breast cancer cells. It inhibited cell growth with IC ₅₀ values ranging from 8nM (RMUG-S) to 0.37μM (HCC1954), depending on the cell line[1]. |
| In vivo | In a patient-derived xenograft (PDX) mouse model (HBCx-34), oral administration of PARG-IN-4 (100mg/kg, once daily for 45 days) led to complete tumor regression, achieving a tumor growth inhibition rate (TGI) of 110%[1]. |

Solubility Information

| | |
|---------------------|---|
| Solubility | DMSO: 16 mg/mL (32.15 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.02 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.0097 mL | 10.0484 mL | 20.0969 mL |
| 5 mM | 0.4019 mL | 2.0097 mL | 4.0194 mL |
| 10 mM | 0.201 mL | 1.0048 mL | 2.0097 mL |
| 50 mM | 0.0402 mL | 0.201 mL | 0.4019 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481